Compass Therapeutics Announces Clinical Collaboration with Merck To Evaluate CTX-471 in Combination with KEYTRUDA^® (Pembrolizumab)

Compass Therapeutics, Inc. announced a clinical trial collaboration and supply agreement with Merck to enablesthe evaluation of the safety and efficacy of Compass’ CTX-471, a fully human monoclonal antibody that binds and activates a novel epitope of the co-stimulatory receptor CD137 in combination with Merck’s anti-PD-1 therapy KEYTRUDA®.